Autolus Therapeutics logo

AUTL - Autolus Therapeutics Share Price

$12.67 -0.2  -1.4%

Last Trade - 4:18pm

Sector
Healthcare
Size
Mid Cap
Market Cap £442.7m
Enterprise Value £266.9m
Revenue £227k
Position in Universe 2901st / 6416
Bullish
Bearish
Unlock AUTL Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AUTL Revenue Unlock AUTL Revenue

Net Income

AUTL Net Income Unlock AUTL Revenue

Normalised EPS

AUTL Normalised EPS Unlock AUTL Revenue

PE Ratio Range

AUTL PE Ratio Range Unlock AUTL Revenue

Dividend Yield Range

AUTL Dividend Yield Range Unlock AUTL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AUTL EPS Forecasts Unlock AUTL Revenue
Profile Summary

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated February 2, 2018
Public Since June 22, 2018
No. of Shareholders: n/a
No. of Employees: 166
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 44,982,378
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AUTL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AUTL
Upcoming Events for AUTL
Similar to AUTL
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.